[April 17, 2015] |
|
SanBio Presents at Annual European Stroke Organisation Conference
SanBio, a leading regenerative medicine company focused on the discovery
and development of new regenerative cell therapies, today announced one
of its clinical investigators presented at the 1st Annual
European Stroke Organisation conference, a meeting of stroke
researchers, physicians, societies and lay organizations from across
Europe. The conference takes place April 17 through 19 in Glasgow,
Scotland.
The presentation, "Clinical Improvement and Cortical Flair
Hyperintensity Associated With Stereotactic Intracranial Injection of
Modified Bone Marrow-Derived Mesenchymal Stem Cells (SB623) in Chronic
Stroke Patients," will be gven by Lawrence Wechsler, MD, professor of
neurology and neurological surgery at the University of Pittsburgh
School of Medicine and founding director of the University of Pittsburgh
Medical Center (UPMC) Stroke Institute. The presentation took place
during the "Rehabilitation and Recovery" scientific session on Friday,
April 17.
At the conference, SanBio also is presenting a poster regarding the
safety outcomes of its Phase 1/2A clinical trial, titled, "Safety of
Stereotactic Intracranial Injection of Modified Bone Marrow-Derived
Mesenchymal Stem Cells (SB623) in Chronic Stroke Patients: A Phase 1/2A
Study."
About SanBio
SanBio is based in Tokyo, with a United States headquarters in San
Francisco. SanBio's research focuses on harnessing the power of adult
stem cells to provide new therapeutic options for the millions of people
suffering from chronic stroke and other debilitating neurological
disorders. Its proprietary stem cell therapy, SB623, is in Stage 2
clinical trials for treatment of chronic stroke and is expected to begin
Stage 2 clinical trials for treatment of traumatic brain injury later in
2015.
[ Back To TMCnet.com's Homepage ]
|